Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 7 Post-Enhancement Visual and Refractive Outcomes

From: Safety and effectiveness of the SUPRACOR presbyopic LASIK algorithm on hyperopic patients

Pre Supracor Patient A Patient B Patient C Patient D
 UDVA 20/20 20/30 20/60 20/25
 UIVA 20/32 20/50 20/50 20/25
 UNVA J5 J10 J10 J10
 Sphere (D) +0.50 +1.25 +1.75 +0.50
 Cylinder (D) −0.25 −0.50 −0.75 −0.75
 Spherical Equivalent (D) +0.375 +1.00 +1.375 +0.125
Pre Enhancement 14 months 6 months 1 year 2 months
 UDVA 20/20 20/25 20/20 20/25
 UIVA 20/25 20/16 20/40 20/25
 UNVA J3 J1 (doubling) J10 J5
 Sphere (D) Plano Plano +0.50 +0.50
 Cylinder (D) −0.25 −0.50 0.00 −0.25
 Spherical Equivalent (D) −0.125 −0.25 +0.50 +0.375
Latest follow up 2.5 years 1 year 3 weeks 6 months
 UDVA 20/20 20/30 20/50 20/30
 UIVA 20/25 20/25 20/30 20/25
 UNVA J1 J1 J2 J1
 Sphere (D) −0.25 −1.00 −0.50 −0.50
 Cylinder (D) −0.25 −0.50 −0.25 −1.00
 Spherical Equivalent (D) −0.325 −1.25 −0.63 −1.00
  1. UDVA= uncorrected distance visual acuity; UIVA= uncorrected intermediate visual acuity; UNVA= uncorrected near visual acuity